Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.
Mello RP, Echegaray MVF, Jesus-Nunes AP, Leal GC, Magnavita GM, Vieira F, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Souza-Marques B, Bandeira ID, Santos-Lima C, Marback RF, Correia-Melo FS, Lacerda ALT, Quarantini LC. Mello RP, et al. Among authors: guerreiro costa lnf. J Psychiatr Res. 2021 Jun;138:576-583. doi: 10.1016/j.jpsychires.2021.05.014. Epub 2021 May 8. J Psychiatr Res. 2021. PMID: 33991996 Clinical Trial.
Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, Sampaio AS, Sanacora G, Turecki G, Loo C, Lacerda ALT, Quarantini LC. Leal GC, et al. Among authors: guerreiro costa lnf. Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582. doi: 10.1007/s00406-020-01110-5. Epub 2020 Feb 20. Eur Arch Psychiatry Clin Neurosci. 2021. PMID: 32078034 Clinical Trial.
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study.
Araújo-de-Freitas L, Santos-Lima C, Mendonça-Filho E, Vieira F, França RJAF, Magnavita G, Cardoso TL, Correia-Melo FS, Leal GC, Jesus-Nunes AP, Souza-Marques B, Marback R, Teles M, Echegaray MV, Beanes G, Guerreiro-Costa LNF, Mello RP, Rabanea T, Lucchese AC, Abreu N, Lacerda ALT, Quarantini LC. Araújo-de-Freitas L, et al. Among authors: guerreiro costa lnf. Psychiatry Res. 2021 Sep;303:114058. doi: 10.1016/j.psychres.2021.114058. Epub 2021 Jun 7. Psychiatry Res. 2021. PMID: 34153630 Clinical Trial.
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP, Leal GC, Correia-Melo FS, Vieira F, Mello RP, Caliman-Fontes AT, Echegaray MVF, Marback RF, Guerreiro-Costa LNF, Souza-Marques B, Santos-Lima C, Souza LS, Bandeira ID, Kapczinski F, Lacerda ALT, Quarantini LC. Jesus-Nunes AP, et al. Among authors: guerreiro costa lnf. Hum Psychopharmacol. 2022 Jul;37(4):e2836. doi: 10.1002/hup.2836. Epub 2022 Feb 18. Hum Psychopharmacol. 2022. PMID: 35179810 Clinical Trial.
Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression.
Souza-Marques B, Telles M, Leal GC, Faria-Guimarães D, Correia-Melo FS, Jesus-Nunes AP, Vieira F, Souza L, Lins-Silva D, Mello RP, Guerreiro-Costa L, Bandeira ID, Lacerda ALT, Sampaio AS, Quarantini LC. Souza-Marques B, et al. J Clin Psychopharmacol. 2022 Jul-Aug 01;42(4):408-412. doi: 10.1097/JCP.0000000000001571. Epub 2022 Jun 21. J Clin Psychopharmacol. 2022. PMID: 35727083 Clinical Trial.
Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
Beanes G, Caliman-Fontes AT, Souza-Marques B, Silva HDS, Leal GC, Carneiro BA, Guerreiro-Costa LNF, Figueiredo AV, Figueiredo CAV, Lacerda ALT, Costa RDS, Quarantini LC. Beanes G, et al. Among authors: guerreiro costa lnf. Clin Neuropharmacol. 2022 Nov-Dec 01;45(6):151-156. doi: 10.1097/WNF.0000000000000517. Epub 2022 Sep 11. Clin Neuropharmacol. 2022. PMID: 36093918 Clinical Trial.
Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study.
Leal GC, Souza-Marques B, Mello RP, Bandeira ID, Caliman-Fontes AT, Carneiro BA, Faria-Guimarães D, Guerreiro-Costa LNF, Jesus-Nunes AP, Silva SS, Lins-Silva DH, Fontes MA, Alves-Pereira R, Cordeiro V, Rugieri-Pacheco S, Santos-Lima C, Correia-Melo FS, Vieira F, Sanacora G, Lacerda ALT, Quarantini LC. Leal GC, et al. Among authors: guerreiro costa lnf. J Affect Disord. 2023 Jun 1;330:7-15. doi: 10.1016/j.jad.2023.02.151. Epub 2023 Mar 4. J Affect Disord. 2023. PMID: 36871913 Clinical Trial.
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial.
Echegaray MVF, Mello RP, Magnavita GM, Leal GC, Correia-Melo FS, Jesus-Nunes AP, Vieira F, Bandeira ID, Caliman-Fontes AT, Telles M, Guerreiro-Costa LNF, Marback RF, Souza-Marques B, Lins-Silva DH, Santos-Lima C, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC. Echegaray MVF, et al. Among authors: guerreiro costa lnf. Trends Psychiatry Psychother. 2023 Sep 17. doi: 10.47626/2237-6089-2022-0593. Online ahead of print. Trends Psychiatry Psychother. 2023. PMID: 37717263 Free article.